ADMA Biologics, Inc. (ADMA)
13.67
+0.43
(+3.25%)
USD |
NASDAQ |
Nov 13, 16:00
13.67
0.00 (0.00%)
After-Hours: 19:59
ADMA Biologics Net Income (Quarterly) : 49.88M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 49.88M |
| June 30, 2026 | 37.82M |
| March 31, 2026 | 45.33M |
| December 31, 2025 | 49.38M |
| September 30, 2025 | 36.43M |
| June 30, 2025 | 34.22M |
| March 31, 2025 | 26.90M |
| December 31, 2024 | 111.90M |
| September 30, 2024 | 35.91M |
| June 30, 2024 | 32.06M |
| March 31, 2024 | 17.81M |
| December 31, 2023 | -17.64M |
| September 30, 2023 | 2.565M |
| June 30, 2023 | -6.371M |
| March 31, 2023 | -6.789M |
| December 31, 2022 | -12.23M |
| September 30, 2022 | -14.90M |
| June 30, 2022 | -13.76M |
| March 31, 2022 | -25.01M |
| December 31, 2021 | -16.65M |
| September 30, 2021 | -17.71M |
| June 30, 2021 | -18.91M |
| March 31, 2021 | -18.38M |
| December 31, 2020 | -19.41M |
| September 30, 2020 | -16.92M |
| Date | Value |
|---|---|
| June 30, 2020 | -20.18M |
| March 31, 2020 | -19.25M |
| December 31, 2019 | -10.56M |
| September 30, 2019 | -11.44M |
| June 30, 2019 | -13.21M |
| March 31, 2019 | -13.07M |
| December 31, 2018 | -18.04M |
| September 30, 2018 | -15.14M |
| June 30, 2018 | -14.75M |
| March 31, 2018 | -17.82M |
| December 31, 2017 | -12.98M |
| September 30, 2017 | -15.20M |
| June 30, 2017 | -9.036M |
| March 31, 2017 | -6.537M |
| December 31, 2016 | -4.559M |
| September 30, 2016 | -4.331M |
| June 30, 2016 | -6.012M |
| March 31, 2016 | -4.612M |
| December 31, 2015 | -4.583M |
| September 30, 2015 | -5.102M |
| June 30, 2015 | -4.679M |
| March 31, 2015 | -3.606M |
| December 31, 2014 | -3.563M |
| September 30, 2014 | -3.385M |
| June 30, 2014 | -3.961M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| BioMarin Pharmaceutical, Inc. | -122.83M |
| Nektar Therapeutics | -40.62M |
| Rhythm Pharmaceuticals, Inc. | -41.37M |
| Arcutis Biotherapeutics, Inc. | 8.801M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 141.10M |
| Total Expenses (Quarterly) | 91.22M |
| EPS Diluted (Quarterly) | 0.2209 |
| Enterprise Value | 3.028B |
| Gross Profit Margin (Quarterly) | 70.77% |
| Profit Margin (Quarterly) | 35.35% |
| Earnings Yield | 5.68% |
| Operating Earnings Yield | 7.26% |
| Normalized Earnings Yield | 5.680 |